Search results for "Survival"

showing 10 items of 3291 documents

Prognostic factors for cryotherapy of colorectal liver metastases.

2004

Abstract Background . Cryotherapy is a local ablative treatment option for non-resectable liver tumours. We aimed to identify prognostic indicators, that may allow better selection or stratification for adjuvant therapies of patients. Methods . Fifty-five patients had cryotherapy for colorectal liver metastases. The patient-, tumour- and operative details were recorded prospectively. Mean follow up was 24 months. A uni- and multivariate analysis for possible prognostic factors was performed. Results . There was a trend towards better survival for patients with unilobar liver metastases, preoperative serum levels of carcinoembrional antigen (CEA) not exceeding 20 ng/ml and patients undergoin…

AdultMalemedicine.medical_specialtyBlood transfusionMultivariate analysisColorectal cancermedicine.medical_treatmentCryotherapyGastroenterologyCryosurgeryCryosurgeryInternal medicinemedicineHumansAgedUnivariate analysisbusiness.industryProportional hazards modelLiver NeoplasmsGeneral MedicineMiddle Agedmedicine.diseasePrognosisSurgeryCarcinoembryonic AntigenSurvival RateOncologySurgeryFemalebusinessColorectal NeoplasmsAdjuvantBiomarkersEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
researchProduct

Long-term outcome after living donor liver transplantation compared to donation after brain death in autoimmune liver diseases: Experience from the E…

2021

Knowledge of living donor liver transplantation (LDLT) for autoimmune liver diseases (AILDs) is scarce. This study analyzed survival in LDLT recipients registered in the European Liver Transplant Registry with autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis (PSC) and the non-autoimmune disorder alcohol-related cirrhosis. In total, 29 902 individuals enrolled between 1998 and 2017 were analyzed, including 1003 with LDLT. Survival from >90 days after LDLT for AILDs in adults was 85.5%, 74.2%, and 58.0% after 5, 10, and 15 years. Adjusted for recipient age, sex, and liver transplantation era, adult PSC patients receiving LDLT showed increased mortality compare…

AdultMalemedicine.medical_specialtyBrain DeathCirrhosisMultivariate analysis[SDV]Life Sciences [q-bio]Medizinliving donorDiseaseAutoimmune hepatitisinflammatory030230 surgeryclinical research/practiceGastroenterologyPrimary sclerosing cholangitis03 medical and health sciences0302 clinical medicinepatient survivalInternal medicinemedicinePrimary Sclerosing CholangitisLiving DonorsImmunology and AllergyRisk-FactorsHumansPharmacology (medical)RegistriesChildRetrospective StudiesTransplantationbusiness.industryLiver DiseasesHazard ratioGraft SurvivalCohort[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologymedicine.disease3. Good healthDonation after brain deathLiver TransplantationTreatment Outcome030211 gastroenterology & hepatologyimmuneMorbidityLiving donor liver transplantationbusinessliver diseaseliver transplantation/hepatologyAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant SurgeonsREFERENCES
researchProduct

Developments in esophageal surgery for adenocarcinoma: a comparison of two decades

2007

Abstract Background The objective of this study was to examine outcomes in patients undergoing esophageal resection for adenocarcinoma at our institution during a 20-year period and, in particular, to address temporal trends in long-term survival. Methods Out of 470 patients who underwent esophagectomy for malignancy between September 1985 and September 2005, a total number of 175 patients presented with esophageal adenocarcinoma. Patients enrolled in this study included AEG (adenocarcinoma of the esophagogastric junction) type I tumors only. Time trends were studied comparing two decades, 9/1985 to 9/1995 (DI) and 10/1995 to 9/2005 (DII). Results The overall survival was significantly more…

AdultMalemedicine.medical_specialtyCancer ResearchTime FactorsEsophageal Neoplasmsmedicine.medical_treatmentAdenocarcinomaMalignancylcsh:RC254-282Disease-Free SurvivalSurgical oncologymedicineGeneticsHumansSurvivorsEsophagusSurvival analysisAgedNeoplasm StagingRetrospective Studiesbusiness.industryRetrospective cohort studyMiddle AgedPrognosislcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseCombined Modality TherapySurvival AnalysisSurgeryEsophagectomyLog-rank testTreatment Outcomemedicine.anatomical_structureOncologyEsophagectomyLymph Node ExcisionAdenocarcinomaFemalebusinessResearch ArticleBMC Cancer
researchProduct

Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: The more, the worse?

2018

BACKGROUND & AIMS Portal vein tumour thrombosis (PVTT) has a significant impact on the prognosis of patients with hepatocellular carcinoma (HCC). The degree of PVTT varies from sub-/segmental invasion to complete occlusion of the main trunk. Aim of this study was to evaluate whether the degree of PVTT correlates with prognosis. METHODS A total of 1317 patients with HCC treated at our tertiary referral centre between January 2005 and December 2016 were included. PVTT was diagnosed by contrast-enhanced computed tomography or magnetic resonance imaging. The extent of PVTT was documented according to the Liver Cancer Study Group of Japan classification: Vp0 = no PVTT, Vp1 = segmental portal vei…

AdultMalemedicine.medical_specialtyCarcinoma HepatocellularAdolescentvirusesPortal veinYoung Adult03 medical and health sciences0302 clinical medicineGermanyComplete occlusionHepatectomyHumansMedicineIn patientAgedRetrospective StudiesAged 80 and overVenous ThrombosisHepatologyLeft portal veinmedicine.diagnostic_testPortal Veinbusiness.industryLiver NeoplasmsMagnetic resonance imagingMiddle AgedPrognosismedicine.diseaseSurvival AnalysisThrombosisSurvival Rate030220 oncology & carcinogenesisHepatocellular carcinomaFemale030211 gastroenterology & hepatologyRadiologybusinessLiver cancerLiver International
researchProduct

Randomised controlled trial of lipiodol transarterial chemoembolisation with or without amiodarone for unresectable hepatocellular carcinoma.

2011

Abstract Background There is no consensus about the most effective method for transarterial chemoembolisation of hepatocellular carcinoma. Aim The aim of this phase II trial was to compare the efficacy and toxicity of lipiodol transarterial chemoembolisation with amiodarone in association with pirarubicin or doxorubicin versus lipiodol transarterial chemoembolisation with anthracycline alone in a control group. Methods Patients with unresectable hepatocellular carcinoma and Child-Pugh A/B7 were considered eligible for the trial. transarterial chemoembolisation was repeated every 6 weeks for a maximum of 4 sessions. Results Thirteen patients were randomised in the amiodarone group, and 14 we…

AdultMalemedicine.medical_specialtyCarcinoma HepatocellularAnthracyclinePirarubicinAmiodaroneKaplan-Meier EstimateAmiodaroneGastroenterologyDisease-Free Survivallaw.inventionExcipientsEthiodized OilRandomized controlled triallawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansChemoembolization TherapeuticAgedHepatologybusiness.industryLiver NeoplasmsGastroenterologyMiddle Agedmedicine.diseaseSurgeryClinical trialTreatment OutcomeDoxorubicinHepatocellular carcinomaLipiodolFemalebusinessmedicine.drugDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Transarterial Chemoembolization in Patients Not Eligible for Liver Transplantation: Single-Center Results

2008

OBJECTIVE. The purpose of this study was to evaluate the effectiveness of transarterial chemoembolization in the care of patients not eligible for liver transplantation.CONCLUSIONS. Prognosis depends on local response, Okuda score, α-fetoprotein level, and tumor size and is independent of the presence of portal venous thrombosis.

AdultMalemedicine.medical_specialtyCarcinoma HepatocellularPalliative careMitomycinmedicine.medical_treatmentContrast MediaLiver transplantationSingle CenterStatistics NonparametricmedicineHumansRadiology Nuclear Medicine and imagingIn patientChemoembolization TherapeuticSurvival analysisAgedAged 80 and overAntibiotics AntineoplasticChi-Square Distributionbusiness.industryLiver NeoplasmsPalliative CareIodized OilGeneral MedicineMiddle AgedPrognosismedicine.diseaseSurvival AnalysisIopamidolSurgeryVenous thrombosisTreatment OutcomeHepatocellular carcinomaFemaleRadiologyTomography X-Ray ComputedbusinessChi-squared distributionAmerican Journal of Roentgenology
researchProduct

A 30-Year, Population-Based Study Shows Improved Management and Prognosis of Hepatocellular Carcinoma

2010

Background & Aims Little is known about the impact of changes in the management of hepatocellular carcinoma (HCC) over time. We assessed trends in the pattern of care and in prognosis at a population level. Methods Data on diagnostic conditions, treatment, and prognosis from 1976–2005 were collected by the population-based digestive cancer registry of Burgundy (France). A nonconditional logistic regression was used to identify factors associated with treatment for cure. A multivariate relative survival analysis was also performed. Results The context of HCC diagnosis has changed; the proportion of asymptomatic patients increased from 5.6% (1976–1985) to 37.2% (1996–2005). The proportion of …

AdultMalemedicine.medical_specialtyCarcinoma HepatocellularPopulationContext (language use)Logistic regressionAsymptomaticInternal medicineEpidemiologymedicineHumanseducationAgedUltrasonographyAged 80 and overeducation.field_of_studyHepatologyRelative survivalHistocytochemistrybusiness.industryGastroenterologyMiddle AgedPrognosismedicine.diseaseSurvival AnalysisConfidence intervalSurgeryRadiographyTreatment OutcomeHepatocellular carcinomaFemaleFrancemedicine.symptombusinessClinical Gastroenterology and Hepatology
researchProduct

Five-Year Survival After Monotherapy for Hepatocellular Carcinoma in the Setting of Cirrhosis

2008

The purpose of this study was to evaluate the long-term results with monotherapy for hepatocellular carcinoma (HCC) in the setting of cirrhosis. We reviewed data of 14 patients who survived for at least 5 years after performance of liver resection (n = 1), transarterial chemoembolization (TACE, n = 3), or liver transplantation (OLT, n = 19). Eight patients were within the Milan criteria, whereas the remaining 6 were beyond the criteria. Tumor stages according to the UICC were I (n = 8), II (n = 5), and IIIA (n = 1). Vascular invasion was not detected in any patient. The HCCs recurred in 2 patients, at 81 and 48 months' posttransplant. Sites of recurrence were the intrathoracic lymph nodes i…

AdultMalemedicine.medical_specialtyCarcinoma HepatocellularTime FactorsCirrhosismedicine.medical_treatmentMedizinMilan criteriaLiver transplantationGastroenterologyInternal medicinemedicineCarcinomaHumansSurvivorsChemoembolization TherapeuticSurvival rateAgedTransplantationbusiness.industryLiver NeoplasmsMiddle Agedmedicine.diseaseLiver TransplantationSurgerySurvival RateTransplantationHepatocellular carcinomaFemaleSurgeryalpha-FetoproteinsNeoplasm Recurrence LocalbusinessLiver cancerFollow-Up StudiesTransplantation Proceedings
researchProduct

Impact of Italian Score for Organ Allocation System on Deceased Donor Liver Transplantation: A Monocentric Competing Risk Time-to-Event Analysis

2019

Background: Liver transplantation (LT) is the only definitive and curative treatment for patients with end-stage liver disease and hepatocellular carcinoma. We aimed to evaluate the impact of the Italian score for organ allocation (ISO) in terms of the waiting-list mortality, probability of LT, and patient survival after LT. Patient and methods: All of the adult patients on the waiting list for LT at our institute from January 2014 to December 2017 were included in the study. The probabilities of death while on the waiting list, dropout from the list, and LT were compared by means of cumulative incidence functions, in a competing risk time-to-event analysis setting. Uni- and multivariable l…

AdultMalemedicine.medical_specialtyCarcinoma HepatocellularTime FactorsWaiting Listsmedicine.medical_treatmentLiver transplantationCompeting risksLogistic regressionSeverity of Illness IndexGroup BEnd Stage Liver DiseaseLiver diseaseRisk FactorsInternal medicinemedicineHumansCumulative incidenceSurvival analysisRetrospective StudiesTransplantationbusiness.industryLiver NeoplasmsMiddle Agedmedicine.diseaseLiver TransplantationItalyHepatocellular carcinomaSurgeryFemalebusiness
researchProduct

Living Donor Liver Transplantation for Hepatocellular Carcinoma in Patients Exceeding the UCSF Criteria

2008

Abstract Background Living donor liver transplantation (LDLT) represents an alternative to expand the organ pool for adult patients with hepatocellular carcinoma (HCC) and end-stage liver disease. The purpose of this study was to demonstrate our institutional experience using criteria exceeding those of the University of California San Francisco (UCSF). Patients and Methods Between September 1998 and December 2006, 22 LDLTs were performed for HCC among patients exceeding the UCSF criteria. Results There were 17 men and 5 women of median age 55 years. Multifocal tumors were present in 19 of 22 patients. Tumor grading was: grade I (n = 8), grade II (n = 10), and grade III (n = 4). Microvascul…

AdultMalemedicine.medical_specialtyCarcinoma HepatocellularTime Factorsmedicine.medical_treatmentMedizinLiver transplantationGastroenterologyDisease-Free SurvivalLiver diseaseInternal medicineLiving DonorsTumor GradingHumansMedicineIn patientSurvivorsNeoplasm StagingTransplantationbusiness.industryPatient SelectionLiver NeoplasmsCancerMiddle Agedmedicine.diseaseLiver TransplantationSurgerySurvival RateHepatocellular carcinomaFemaleSurgerybusinessLiver cancerLiving donor liver transplantationTransplantation Proceedings
researchProduct